Abstract. A complete set of chimeras was made be~ tween the lysosomal membrane glycoprotein LEP100 and the plasma membrane-directed vesicular stomatitis virus G protein, combining a glycosylated lumenal or ectodomain, a single transmembrane domain, and a cytosolic carboxyl-terrninal domain. These chimeras, the parent molecules, and a truncated form of LEPI00 lacking the transmembrane and cytosolic domains were expressed in mouse L cells. Only LEP100 and chimeras that included the cytosolic 11 amino acid carboxyl terminus of LEP100 were targeted to lysosomes. The other chimeras accumulated in the plasma membrane, and truncated LEP100 was secreted. Chimeras that included the extracellular domain of vesicular stomatitis G protein and the carboxyl terminus of LEP100 were targeted to lysosomes and very rapidly degraded. Therefore, in chimera-expressing cells, virtually all the chimeric molecules were newly synthesized and still in the biosynthesis and lysosomal targeting pathways. The behavior of one of these chimeras was studied in detail. After its processing in the Golgi apparatus, the chimera entered the plasma membrane/endosome compartment and rapidly cycled between the plasma membrane and endosomes before going to lysosomes. In pulse-expression experiments, a large population of chimeric molecules was observed to appear transiently in the plasma membrane by immunofluorescence microscopy. Soon after protein synthesis was inhibited, this surface population disappeared. When lysosomal proteolysis was inhibited, chimeric molecules accumulated in lysosomes. These data suggest that the plasma membrane/early endosome compartment is on the pathway to the lysosomal membrane. This explains why mutations that block endocytosis result in the accumulation of lysosomal membrane proteins in the plasma membrane.
tween the lysosomal membrane glycoprotein LEP100 and the plasma membrane-directed vesicular stomatitis virus G protein, combining a glycosylated lumenal or ectodomain, a single transmembrane domain, and a cytosolic carboxyl-terrninal domain. These chimeras, the parent molecules, and a truncated form of LEPI00 lacking the transmembrane and cytosolic domains were expressed in mouse L cells. Only LEP100 and chimeras that included the cytosolic 11 amino acid carboxyl terminus of LEP100 were targeted to lysosomes. The other chimeras accumulated in the plasma membrane, and truncated LEP100 was secreted. Chimeras that included the extracellular domain of vesicular stomatitis G protein and the carboxyl terminus of LEP100 were targeted to lysosomes and very rapidly degraded. Therefore, in chimera-expressing cells, virtually all the chimeric molecules were newly synthesized and still in the biosynthesis and lysosomal targeting pathways. The behavior of one of these chimeras was studied in detail. After its processing in the Golgi apparatus, the chimera entered the plasma membrane/endosome compartment and rapidly cycled between the plasma membrane and endosomes before going to lysosomes. In pulse-expression experiments, a large population of chimeric molecules was observed to appear transiently in the plasma membrane by immunofluorescence microscopy. Soon after protein synthesis was inhibited, this surface population disappeared. When lysosomal proteolysis was inhibited, chimeric molecules accumulated in lysosomes. These data suggest that the plasma membrane/early endosome compartment is on the pathway to the lysosomal membrane. This explains why mutations that block endocytosis result in the accumulation of lysosomal membrane proteins in the plasma membrane.
T HE limiting membrane of the lysosome is greatly enriched in a class of heavily glycosylated, extensively sialylated integral membrane proteins (reviewed in Kornfeld and Mellman, 1989) . Although the function of these glycoproteins is not known, they may protect the lysosomal membrane from hydrolysis (Kornfeld and Mellman, 1989; Granger et al., 1990) . These glycoproteins are also found in lower abundance in endocytic vesicles and in the plasma membrane (Lippincott-Schwartz and Fambrough, 1987; Griffiths et al., 1988; Mane et al., 1989) . The avian lysosomal membrane glycoprotein LEP100 and its encoding DNA have been characterized Fambrough, 1986, 1987; Fambrough et al., 1988; Zot and Fambrough, 1990) . LEP100 has a cleaved amino-terminal signal peptide, a lumenal domain of 361 amino acids with 17 N-linked oligosaccharides, a single transmembrane domain of 24 amino acids, and a cytoplasmic carboxyl terminus of 11 amino acids. Homologues of LEP100 occur in mammals, including human hLAMP-1 (Viitala et al., 1988; Fukuda et al., 1988) , rat lgpl20 (Howe et al. 1988) , and mouse mLAMP-1 (Chen et al., 1988) . Amino acid sequence similarity among these four lysosomal membrane glycoproteins increases from the amino terminus to the carboxyl terminus, with the cytoplasmic domain showing complete sequence identity.
The intracellular trafficking leading to the lysosomal delivery of many soluble lysosomal enzymes involves the mannose 6-phosphate (M6P) t signal/receptor system. Newly synthesized lysosomal enzymes are modified by the addition of phosphate to the 6-hydroxy position on mannose residues (von Figura and Hasilik, 1986) . This M6P signal is recogn.zed by the M6P receptor in the trans-Golgi network (TGN) (Griffiths and Simons, 1986) , and M6P-tagged enzymes are transported by vesicular traffic to late endosomes (Lemansky et al., 1987; Marquardt et al., 1987; Griffiths et al., 1988) . Here the enzymes dissociate from their receptor and are transported on to lysosomes while the receptor is recycled to the TGN (Brown et al., 1986; Duncan and Kornfeld, 1988; Goda and Pfeffer, 1988) . The lysosomal membrane glycoproteins, however, do not contain the M6P modification and must be targeted to lysosomes by a different mechanism (D'Souza and August, 1986; I. Abbreviations used in this paper: CHX, cycloheximide; LAE lysosomal acid phosphatase; M6P, mannose 6-phosphate; TGN, trans-Golgi network; VSV-G, vesicular stomatitis virus coat glycoprotein. Fambrough, 1986; Barriocanal et al., 1986; Granger et al., 1990) .
Previous reports have documented the lysosomal targeting of chimeric proteins consisting of the ectodomain of a plasma membrane protein linked to the transmembrane and cytoplasmic domains of LEP100 or the cytoplasmic domain ofhLAMP-1 (Mathews, P. M., and D. M. Fambrough, 1988. J. Gen. Phys. 92:18a; Williams and Fukuda, 1990) . We report here on a complete battery of chimeras between LEP100 and the plasma membrane protein vesicular stomatitis virus coat glycoprotein (VSV-G) in which each of the three domains of LEP100 was replaced by the corresponding domain of VSV-G and vice versa. The behavior of these chimeras and a truncated form of LEP100 that was secreted suggests that only the 11-amino acid cytoplasmic domain of LEP100 is involved in lysosomal targeting.
The mechanism whereby the cytoplasmic tail of LEP100 directs the lysosomal targeting of newly synthesized molecules remains unknown. The single tyrosine in the cytoplasmic tail has been shown to be necessary for the lysosomal targeting of hLAMP-1 and lgpl20. Mutating this tyrosine resulted in proteins that accumulate in the plasma membrane, as did eliminating most of the cytoplasmic tail of hLAMP-1 (Williams and Fukuda, 1990; Hunziker et al., 1991) . This mistargeting has been interpreted as resulting from a defect in sorting in the TGN: newly synthesized molecules fail to target to lysosomes at the TGN and are therefore transported to the plasma membrane along the constitutive secretory pathway. This interpretation was based predominantly on the work of Green et al. (1987) , in which metabolically labeled lgpl20 was found to appear rapidly in a lysosomal subcellular fraction, and very little lgpl20 was found in the plasma membrane and early endosomes. Recently Harter and Mellman (1992) revised this interpretation, proposing a branched pathway of targeting of lgpl20 partly via the TGN to late endosomes and lysosomes and partly via the plasma membrane.
Contrary to these interpretations, recent experiments indicate that most or all molecules of a very closely related lysosomal membrane glycoprotein (LAMP-2) pass through the basolateral plasma membrane of polarized MDCK cells before lysosomal delivery (Nabi et al., 1991) . LAMP-2 molecules, which share some sequence identity with LEP100, have been cloned from a number of mammalian species Cha et al., 1990; Granger et al., 1990) . Another lysosomal protein, human lysosomal acid phosphatase (LAP), travels to the plasma membrane as an integral membrane protein prior to endocytosis, lysosomal delivery, and cleavage to a soluble form (Waheed et al., 1988; Braun et al., 1989) . In our study we made use of a LEP100 deletion mutant and chimeras between LEP100 and VSV-G protein to study the pathway by which the lysosomal targeting signal in LEP100 directs molecules to the lysosomes. These three cases (LAMP-2, LAP, and LEPI00) suggest that the delivery of integral membrane proteins to the lysosome via the cell surface is a major pathway in animal cells.
Materials and Methods

Mutagenesis and Construction of Chimeric cD NAs
The eDNA encoding VSV-G was the generous gift of Dr. J. K. Rose (Yale University School of Medicine, New Haven, CT) (Rose and Shafferman, 1981; Rose and Bergmann, 1982) . Mutations creating unique restriction endonuclease sites were introduced by the method of Kunkel et al. (1987) . Briefly, dUTP-containing single stranded eDNA was prepared, mutagenic synthetic oligonucleotides were used to prime second strand synthesis, and mutated DNA was recovered after transforming dUTP-intolerant bacteria. A PvuII restriction site was introduced into the VSV-G eDNA just 5' to the region encoding the transmembrane domain; this site is in-frame with a unique PvuII site located just 5' to the region encoding the transmembrane domain in the LEP100 eDNA. HpaI sites were introduced into both cDNAs near the 3' end of the region encoding the transmembrane domain. Chimeric cDNAs were constructed using these restriction sites (see Fig. 1 ).
The chimera in which the cytoplasmic domain of LEP100 replaced that of VSV-G was constructed using the polymerase chain reaction (PCR) (Saiki et al., 1988) . A hybrid primer with the sequence 5'-GGA CTA TIC TTG GTT CTC AGA AAG AGG AGC CAC-3' was used to generate a 448-bp fragment consisting of a 18-bp region of identity to the Y-most transmembrane encoding region of VSV-G, the entire cytoplasmic domain and 3' untranslated regions of the LEP100 eDNA, and an additional 68 lap extending beyond the polylinker in pSVDF-4 (see below). This fragment was isolated and used as primers with VSV-G cDNA in the Bluescript vector (Stratagene, La Joila, CA) for six PCR cycles. Then a large fragment encoding most of the lumenal and all of the transmembrane regions of VSV-G and the cytoplasmic domain of LEP100 was generated by adding appropriate primers and carrying out 30 additional PeR cycles. This fragment was cut with NcoI and EcoRl and cloned into Bluescript containing the 5'-609 bp of VSV-G (up to the unique Ncol site).
To generate the DNA encoding a secretory form of LEP100, a PCR fragment representing just the lumenal encoding domain of LEP100 was generated, using as 3' end primer the oligonucleotide 5'-AGG GAA TIE TTA CTA CAT GTT GTT TTC ATe CAG-3' that introduced two tandem stop codons followed by an EcoRl site after the last codon preceding the transmembrane encoding region. This fragment was digested with BglII and EcoR1 and cloned into the Bluescript vector containing the 5'-790-bp EcoR1-BglII fragment of the LEPI00 cDNA.
The nucleotide sequences of all the splice regions of the chimeric DNAs and all the PCR-generated coding regions were confirmed by DNA sequencing (Sanger et al., 1977) . The structures of the normal, mutant, and chimeric proteins are summarized in Fig. 1 along with the nomenclature used for them in this report.
Expression of DNAs in Ltk-Cells
Mouse Ltk-cells (Kit et al., 1963) were maintained in DME, 10% FBS, and 50 #g/ml gentamicin (Gibco Laboratories, Grand Island, NY) at 37~ in a 5 % CO2 atmosphere.
The cDNAs encoding LEPI00, VSV-G, and the chimeras were cloned into the mammalian expression vector pSVDF-4 (Takeyasu et al., 1987) , permitting butyrate-inducible expression driven by the SV-40 early promoter (Gorman et al., 1983) . For stable lines, mouse Ltk-cells were cotransfected using either a calcium phosphate precipitate (Small and Scangos, 1984) or lipofectin (Gibco-BRL, Rockville, MD) used according to manufacturers protocol, with ,x, 20/~g of expression plasmid DNA and 2/~g of pHSVtk5' A 0.2 DNA (McKnight, 1980) per 100-mm tissue culture dish of sub-confluent Ltk-cells. After 24 h the medium was replaced by HAT medium (Boehringer Mannheim Biochemicals, Indianapolis, IN). HAT-resistant clones (Littlefield, 1964) were isolated, expanded, and assayed for expression of LEP100 or VSV-G epitopes by immunofluorescenee microscopy.
The eDNA encoding truncated LEP100 was cloned into an EcoR1 site introduced just 3' of the human cytomegalovirus immediate early promoter in the expression vector pCB6 (Brewer and Roth, 1991) . L cell lines expressing truncated LEP100 were established by lipofectin-mediated transfection and selection in 400 t~g/ml G418 (Sigma Chemical Co., St. Louis, MO) in DME 10% FBS. Approximately 150 colonies from a single 100-mm tissue culture dish were pooled for use in immunofluorescence and metabolic labeling experiments. Expression required butyrate induction (10 mM for 24 to 48 h).
Transient expression was employed in some immunofluorescence experiments. L cells were plated on glass coverslips in 35-mm tissue culture dishes, 4/zg DNA was added as lipofectin/DNA complex in 1 ml DME, 1 ml DME with 10% FBS was added 4 h later, and at 24 h the growth medium was replaced with DME 10% FBS containing 10 mM butyrate. After an additional 36 to 48 h these cultures were used for inununofluorescenee microscopy. The recombinant vaccinia virus/T7 RNA polymerase expression system (Fuerst et al., 1986; Moss, 1991) was used for short-term expression of high levels of protein. Chimeric cDNAs were cloned into the Bluescript vector downstream from the 1"7 promoter. Newly confluent Ltk-cells growing on 25-mm-diam glass coverslips were infected with the recombinant vaccinla virus at a multiplicity of 10 pfu/cell in 0.6 ml DME. 30 min later, transfection was begun by adding 4 to 5 #g DNA, 10 #1 lipofectin in 1 mi DME. After 4 h, 1 ml DME 10% FBS was added. In "pulse expression" experiments (see Results), 75 /~g/ml cycloheximide (Sigma Chemical Co.) was added at this time. When leupeptin was used to prevent lysosomal degradation of the ectodomaln of VSV-G, 20 ttM leupeptin (Sigma Chemical Co.) was added 3 to 4 h before infection and maintained throughout the experiment.
Immunofluorescence Microscopy
Anti-LEP100 monoclonal IgG (LEP100-mAb) (Lippincott-Schwartz and Fambrough, 1986 ) recognizes a lumenal epitope on LEP100 and does not cross-react with murine Ltk-cells, mAb I1 (VSV-G-mAb), the hybridoma a gift of Dr. D. S. Lyles (Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC), binds to an extracellular epitope of VSV-G ( LeFrancois and Lyles, 1982) . Antibodies were purified from ascites fluid as previously described by Lippincott-Schwartz and Fambrough (1986) . FITC or TR1TC (Molecular Probes, Eugene, OR) was conjugated to purified antibody as described by Anderson and Fambrough (1983) . FITC and TRITCconjugated goat anti-monse-IgG sera were purchased from Cappel Laboratories (Malvern, PA). For location of endogenous m-LAMPI in mouse L cells, rat monoclonal anti-m-LAMP1 (Chen et al., 1985) and FITC-conjugated goat anti-rat-IgG serum (Cappel Laboratories) were used.
Cells grown on 25-mm coverslips were fixed in 1% fresh formaldehyde, 100 mM sucrose, 20 mM Na phosphate (pH 7.2) at room temperature for 10 min, rinsed, labeled for 30-60 min with 5 ttg/mi mAb in Hepes-buffered (20 mM pH 7.2) MEM containing 10% horse serum, and washed repeatedly with Hepes/MEM containing 10% horse serum. Cells were permeabilized by the addition of 0.125% saponln (wt/vol) (Sigma Chemical Co.) to the antibody containing and the wash solutions. For indirect immunnfluorescence labeling, coverslips were washed after primary antibody binding, and secondary antibody was then bound followed by 30 min of washes. Cells were mounted in 90% glycerol, 10% PBS, 1 mg/ml p-phenylene diamine and examined with a (Carl Zeiss, Oberkochen, Germany) epifluorescence microscope.
Metabolic Labeling and Immunoprecipitation
Approximately 5 x 105 cells were plated in 35-ram tissue culture dishes and after 16 h were induced with 10 mM butyrate for 36 to 48 h. Cultures were incubated in methionine-free MEM containing 10 mM butyrate for 30 min before a 15-rain incubation with 100-200 #Ci/mi [35S]methionine and [35S]cysteine (TRANa5S-LABEL) (ICN Biomedicals, Inc., Costa Mesa, CA). After four rinses with DME 10% FBS at 4~ cells were grown in DME, 10% FBS for the chase times specified in the text. For some experiments, cells were treated with 20 #M leupeptin beginning 4-5 h before methionine starvation and continuing through the labeling and chase periods.
35S-labeled ceils were rinsed once with PBS, extracted with 1 ml buffer A (150 mM NaC1, 50 mM Tris, 10 mM EDTA, 1% Triton X-100, pH 7.5) containing protease inhibitors (0.3 mg/ml benzamidine, 0.6 mg/ml N-ethylmaleimide, 1.0 mg/mi bacitracin), and the extracts were frozen. Extracts were thawed and centrifuged at 12,000 g 10 rnin. Each superuatant was mixed with 50/~g mAb covalently coupled to Sepharose 4B beads (Fambrough and Bayne, 1983 ) and incubated at 4~ overnight. Imrnunobeads were washed eight times with buffer A, twice with PBS, and eluted with SDS sample buffer (10% [vol/vol] glycerol, 30 mg/mi SDS, 5% [vol/vol] 2-mercaptoethanol, 62 mM Tris, pH 6.8). Immune precipitates were analyzed by SDS-PAGE and fluorography. Radioactivity in the bands was quantified with a Molecular Dynamics PhosphorImager and the ImageQuant software package. Purified monoclonal IgGs were iodinated by the Iodogen method (Salicinski et al., 1981) . Specific activities of iodinated antibodies were determined from knowledge of the antibody concentration (input antibody amount determined spectrophotometrically) and the radioactivity measured in aliquots of the antibody solution after iodination. These values were typically on the order of 1 cpm/106 antibody molecules. Cells grown in 35-mm tissue culture dishes were fixed at room temperature for 10 rain (as for immunofluorescence microscopy) and incubated for 1-2 h with 125I-mAb (5 ttg/ml) in MEM, 10% horse serum, 20 mM Hepes (pH 7.2). After unbound antibody was removed by three 10 min washes in 1-2 liters of medium at 4~ bound t25I-mAb was eluted with 2 ml of 1 N NaOH and counted in a gamma counter. To permeabilize cells, saponin (0.125% wt/vol) was added to the binding medium. Non-specific binding was determined using a 50-or 100-fold excess unlabeled mAb in the binding solution. Data points represent the average of two or three measurements of non-specific binding subtracted from the average of three to five measurements of total binding.
12~I-mAb Binding
Results
Only LEPIOO/VSV-G Chimeras Containing the Cytoplasmic Domain of LEPIO0 Are Targeted to Lysosomes
VSV-G was chosen for the construction of chimeric molecules because of the overall similarity in topography to LEP100, and because, unlike LEP100, VSV-G accumulates in the plasma membrane of transfected cells (Rose and Bergmann, 1982) . Chimeric cDNAs were constructed in which regions of the DNA encoding the three domains of LEP100 (lumenal, transmembrane, and cytoplasmic) were replaced singly and in combinations by DNA encoding the corresponding domains of VSV-G (Fig. 1 ). The resulting chimeras were expressed in mouse L cells, and their cellular locations were determined by immunofluorescence microscopy with monoclonal antibodies specific for either the lumenal domain of LEP100 or the extracellular domain of VSV-G. For all chimeras containing the ectodomain of VSV-G, the protease inhibitor leupeptin was added to cells 16 h before fixation to prevent proteolytic destruction of this domain in lysosomes (see below). When expressed in L cells (Fig. 2 ) VSV-G showed the expected cell-surface localization, while LEP100 showed a lysosomal distribution. (In numerous experiments co-localization of LEP100 and endogenous mouse LAMP-1 was found; occasionally one or two internal structures showed selective immunolabeling with LEP100 or LAMP-1.)
Three of the chimeras (L/V/V, L/L/V, and V/L/V) accumulated in the plasma membrane (Fig. 2 ). These chimeras have in common the cytoplasmic domain of VSV-G. The apparent cell surface distribution of VSV-G, L/V/V, and L/L/V was quantified by ~25I-VSV-G mAb binding to intact and permeabilized cells. After 48 h of butyrate induction and 16 h of leupeptin treatment, >/75 % of molecules were in the plasma membrane (Table I) .
The three chimeras incorporating the cytoplasmic domain of LEP100 (V/L/L, V/V/L, and L/V/L) accumulated in lysosomes ( Fig. 2) , co-localizing with mLAMP1. Although LEP100 and V/L/L were predominantly intracellular, t25I-antibody binding experiments detected some molecules at the cell surface (Table I ). The presence of these molecules in the plasma membrane is similar to the situation for LEP100 in chicken embryo fibroblasts, where ~2-3% of molecules were found on the surface (Lippincott-Schwartz and Fambrough, 1986 .
The Lumenal Domain of LEPIO0 Is Secreted When Expressed as a Truncated Protein
The lumenal domain of LEP100 appears to lack lysosomal targeting information, since L/V/V and L/L/V chimeras do not accumulate in lysosomes. However, it is possible that tar-NAME: 
Figure 1. Nomenclature and amino acid sequences of LEP-100/VSV-G chimeric proteins. The amino acid sequences for LEP100, VSV-G, and the chimeras are shown beginning a few amino acid amino terminal to the transmembrane domain (shaded). Constructions of chimeras employed PvulI sites in the DNA encoding the lumenal domain of LEPI00 and the extracellular domain of VSV-G and Hpa I sites in the DNA encoding the transmembrane domains (arrows indicate corresponding amino acid locations). Chimeras are named according to the scheme lumenal-extracellular domain/ transmembrane domain/cytoplasmic domain with "L" for LEP100 and "V" for VSV-G; e.g., L/V/L consists of the lumenal domain of LEP100/transmembrane domain of VSV-G/cytoplasmic domain of LEP100. Truncated LEP100 consists of the entire lumenal domain without the transmembrane of cytoplasmic domains. The asparagine residue (underlined) in the transmembrane domain of L/L/V, V/L/V and L/V/L is an amino acid change resulting from the generation of the HpaI site.
geting information in the lumenal domain of LEP100 might be overridden by information in the cytoplasmic domain of VSV-G. If the lumenal domain of LEP100 contains intrinsic lysosomal targeting information and reaches the lysosome by a route analogous to that taken by M6P-tagged lysosomal enzymes, then the lumenal domain expressed alone should accumulate in lysosomes. Otherwise, this domain, expressed as a truncated protein, should be secreted. To test these possibilities, we constructed a truncated LEP100 consisting of the entire lumenal domain without the transmembrane and cytoplasmic domains (Fig. 1) . When truncated LEP100 was expressed in mouse L cells, immunofluorescence labeling revealed a reticular pattern and nuclear ring, indicative of predominantly ER localization. No lysosomal pattern of labeling was detected even when cells were cultured in the presence of leupeptin for 16 h before immunofluorescence microscopy; and when cycloheximide was also included in the medium for the final few hours, immunoreactivity disappeared, consistent with secretion of truncated LEP100.
The fate of the truncated LEP100 protein was verified by pulse-chase metabolic labeling experiments. After a 30-min [35S] methionine, [35S]cysteine pulse but no chase, truncated LEP100 was recovered from the cell lysate. The truncated LEP100 isolated from the cells was the high mannose intermediate form, migrating in SDS-PAGE with an Mr of 85 kD, 6 kD less than that of the high mannose form of fulllength LEP100 expressed in L cells. During the chase period the amount of truncated LEP100 associated with the cells decreased rapidly (Fig. 3, A and B) . The complex carbohydrate form of truncated LEP100 was not apparent in immunoprecipitates from cell lysates even with overexposure of x-ray film. However, this form with Mr of 100-110 kD appeared in the medium during the 1-2-h chase and remained relatively stable to 10 h (Fig. 3, A and B) . Thus, there appears to be no pathway for transport of the lumenal domain of LEP100 from the Golgi apparatus to lysosomes.
The VSV-G Ectodomain of V/L/L Is Rapidly Degraded in Lysosomes
The chimera V/L/L did not accumulate sufficiently in lysosomes for detection by immunofluorescence microscopy except when the protease inhibitor leupeptin was present in the medium (see Fig. 2 ). Presumably, the VSV-G ectodomain was degraded rapidly upon delivery to the lysosome. To study this, L cells from a cell line expressing V/L/L were treated for increasing times with leupeptin and total V/L/L molecules quantified by ~25I-VSV-G-mAb binding (Fig. 4) . The number of V/L/L molecules tripled by 12 h, beginning a few hours after addition of leupeptin, and doubled again by 16 h (see Table II ). The lag in accumulation was presumably due to slow onset of leupeptin inhibition of proteolysis. (For this reason, treatment with leupeptin was begun 4 h before metabolic labeling or transient expression with the recombinant vaccinia virus/T7 system) (see below).
If V/L/L molecules are targeted to lysosomes and rapidly degraded there, the population of V/L/L in cells not treated with leupeptin should be comprised of V/L/L molecules in the biosynthetic pathway and in the lysosomal targeting pathway. Treatment of expressing ceils with the protein synthesis inhibitor cycloheximide (CHX) should result in the disappearance of V/L/L molecules as they transit these pathways and arrive in lysosomes. The kinetics of disappearance of V/L/L in CHX-treated cells is shown in Fig. 5 . Approximately 80% of the molecules were lost within 90 min. The kinetics of loss of V/L/L molecules would be expected to be complex, reflecting the transport of newly synthesized V/L/L molecules through the biosynthetic pathway and their delivery to the lysosome. Transport events preceding delivery to the lysosome are likely to be rate limiting and the actual degradation of the VSV-G ectodomain in the lysosome may be a very rapid event. This interpretation is supported by pulse-chase metabolic labeling experiments described below. The chimera V/V/L was expressed using the vaccinia virus/T7 expression system. For this photomicrograph, V/V/L expression was allowed to proceed for 4 h, then cycloheximide was added for an additional 4 h, followed by fixation and fluorescent antibody labeling. Protein synthesis was blocked with cycloheximide to allow newly synthesized V/V/L molecules to move out of the biosynthetic pathway and into lysosomes, simplifying the immunofluoresence pattern. Bar, 10 #m. In the CHX treatment experiments a small fraction of V/L/L molecules was relatively long lived. Pulse-chase metabolic labeling experiments did not reveal a subset of V/L/L molecules which were long-lived without leupeptin treatment (see Fig. 6 ). Among possible explanations for this discrepancy is that CHX treatment might have resulted in depletion of lysosomal hydrolases necessary for the rapid degradation of the VSV-G ectodomain, thus extending the stability of V/L/L in the lysosome. Fig. 6 shows SDS-PAGE analysis of V/L/L from L cells pulse-labeled for 15 min with [35S]methionine and [35S]cysteine followed by various chase times. Without the addition of leupeptin, 35S-labeled V/L/L was no longer detected after a 2-h chase. This is consistent with the disappearance of the majority of VSV-G-mAb binding sites within 90 min after the addition of CHX (Fig. 5) . Fully glycosylated V/L/L first appeared after 20 min of chase, indicating passage into T i m e in L e u p e p t i n ( h o u r s ) Cultures of V/L/L-expressing cells were induced for 48 h with butyrate and some cells were treated for the last 16 h with 20/~M leupeptin. The numbers of specific total ~I-VSV-G-mAb binding sites and cell surface binding sites were determined in saponin permleabilized and non-permeabilized cells as described in Materials and Methods. l.,r treatment results in some cell loss from tissue culture dishes (<20%) as ascertained by counting cell numbers on multiple duplicate dishes with and without leupeptin treatment. The data for leupeptin treatment are adjusted to reflect this. the Golgi apparatus by this time. Degradation products, that appear in SDS-PAGE as a smeared band migrating ahead of the mature form of V/L/L, were apparent after 40 to 50 min of chase. In cells treated with leupeptin, asS-labeled V/L/L remained throughout a 2.5-h chase period (Fig. 6 B) and was still recovered after a 10-h chase.
Table L Cell Surface Expression ofLEPIO0, VSV-G, and Chimeras in Stably Expressing L Cell Lines
A decrease in apparent molecular weight of 35S-labeled V/L/L occurred during the chase with leupeptin present (Fig. 6 B) . This indicates that V/L/L was partially degraded to a "clipped" form (Mr, 60 kD) that retained the epitope recognized by VSV-G-mAb. The clipped protein was •7 kD smaUer than fully glycosylated V/L/L and probably resulted from the removal of the amino terminal region of the protein, since a polyclonal anti-serum raised against a peptide corresponding to the cytoplasmic tail of LEP100 (Nabi et al., 1991) bound to the clipped form of V/L/L in immunoblots. Removal of the two N-linked oligosaccharides would also result in about a 7 kD decrease in molecular weight, a possibility which was not ruled out. Clipped V/L/L first appeared after 60 to 70 rain of chase and became the only form of the molecule present by the end of a 10-h chase period. If the clipping occurs in the lysosomes, the delivery of V/L/L to lysosomes must begin less than 75 to 85 min after synthesis.
Taken together, these experiments support the hypothesis that V/L/L molecules are targeted to lysosomes through a biosynthesis/transport process of 60-80-min duration and that, unless leupeptin is present, V/L/L molecules are degraded within minutes of reaching the lysosomes.
Some Newly Synthesized V/L/L Molecules Are Found at the Cell Surface
Since V/L/L molecules appear to be degraded quickly upon arrival in lysosomes, the detection of V/L/L molecules at the cell surface of cells not treated with leupeptin would strongly suggest that newly synthesized V/L/L molecules can pass through the plasma membrane before lysosomal delivery. We determined the relative number of V/L/L molecules in the plasma membrane of cells expressing V/L/L with or without leupeptin treatment by measuring the binding of t25I-VSV-G-mAb to non-permeabilized as well as permeabilized cells (Table II) . 0.7 % of the total VSV-G-mAb binding sites were found at the cell surface in leupeptin treated ceils while 3.3 % of the total VSV-G-mAb binding sites were found at the cell surface without leupeptin treatment. As would be expected, the total number of VSV-G-mAb binding sites increased substantially (sixfold in 16 h of leupeptin treatment). The absolute number of V/L/L molecules at the cell surface, however, did not change dramatically (only 1.3-fold). Thus, the steady state level of V/L/L in the plasma membrane is relatively independent of the accumulation of V/L/L molecules in lysosomal membranes.
A Wave of Recently Synthesized V/L/L and LEPIO0 Molecules Passes through the Cell Surf ace following a Synchronized t~lse of Expression
The transient expression of recently synthesized V/L/L or LEP100 molecules in the plasma membrane was visualized by immunofluorescence microscopy following synchronized expression with the recombinant vaccinia virus/T7 system. L cells pre-treated for 4 h with leupeptin were infected with recombinant vaccinia virus and 30 min later transfected with V/L/L-DNA or LEP100-DNA cloned just 3' to the T7 promoter in pBluescript. In these experiments the T7 RNA polymerase-driven synthesis of V/L/L or LEP100 was allowed to proceed for a maximum of 4 h, terminated by addition of CHX. At 4 h the predominant intracellular immunofluorescence was in the ER (identified by the presence of a circum-nuclear ring) and intense perinuclear labeling taken to be Golgi apparatus (Fig. 7 A) . Lysosomal labeling was not apparent. Labeling of the plasma membrane was strong at this time, however (Fig. 7, B and D) . Ceils still expressed V/L/L at the surface 1 h after the addition of CHX (Fig. 7 E) . After 2 h in CHX almost no surface labeling could be detected (Fig. 7 F) and the characteristic lysosomal pattern of immunofluorescence was seen (see Fig. 9 C) . Comparable results were obtained for LEP100 expression. The expression of V/L/L at the cell surface was independent of the lysosomal accumulation of V/L/L. Without leupeptin treatment V/L/L was readily detected both on the cell surface and in the ER and Golgi regions, but it did not accumulate in lysosomes and it disappeared completely within 2 h of CHX treatment.
Cell Surface V/L/L Rapidly Cycles Between the Plasma Membrane and Endosomes and Is Transported more Slowly to Lysosomes
In chicken fibroblasts a few percent of LEP100 molecules are found in the plasma membrane, and these undergo continuous, rapid exchange with a larger population of molecules in early endosomes Fambrough, 1986, 1987) . Cell-surface V/L/L molecules were also found to exchange rapidly with intracellular molecules (Fig. 8 A) . When cell-surface V/L/L molecules were saturated with VSV-G-mAb at 4~ and the cells subsequently warmed to 37~ a new population of binding sites for VSV-G-mAb appeared at the surface with a half-time of two to three minutes. In this experiment a small fraction of the newly appearing molecules should be attributable to newly synthesized molecules arriving from the Golgi apparatus. The kinetics of such a component should be linear (whereas recycling kinetics are exponential) and its magnitude might be •20% of the molecules detected in the warm-up period, an effect too small to be seen clearly in experiments such as shown in Fig. 8 A. The rate of internalization of 12sI-VSV-G-mAb bound to V/L/L molecules from the cell surface at 37~ was also very rapid (Fig. 8 B) .
In chicken embryo fibroblasts, LEP100 is internalized from the plasma membrane and transported to lysosomes. When cells were exposed to LEP100-mAb, the antibody was carried to lysosomes and accumulated there if cells were treated with leupeptin (Lippincott-Schwartz and Fambrough, 1987) (Fig. 9 C) . The same sort of process occurred in cells expressing the V/L/L chimera: grown in medium containing VSV-G-mAb and leupeptin, the cells accumulated VSV-G-mAb and showed the punctate, lysosomal pattern of fluorescence when subsequently permeabilized and labeled with fluorescem anti-mouse-IgG second antibody (Fig. 9, A  and B) .
Cell Surface Appearance of Newly Synthesized V/L/L Is Not an Artifact of Overexpression
In the recombinant vaccinia expression system there is massive synthesis of V/L/L (making it easy to demonstrate the cell surface appearance of newly synthesized V/L/L by ira- munofluorescence microscopy) (Fig. 7) . It is conceivable that this level of expression might swamp an intracellular sorting mechanism and lead to misdirection of V/L/L molecules to the cell surface. However, with the exception of experiments documented in Fig. 7 , the experiments describing the behavior of V/L/L molecules were conducted with stable L cell lines expressing V/L/L in response to induction by butyrate. To assess the effect of expression level on appearance of V/L/L at the cell surface in these cells, we conducted a series of experiments at different levels of expression. In these experiments we measured the average number of V/L/L molecules per cell (Table III) . Expression levels appeared to be less than or comparable to the expected endogenous level of expression of LEP100 type molecules (see Discussion).
Then we performed experiments to assess the relative number of V/L/L molecules coming to the plasma membrane en route to lysosomes at lower and higher levels of expression in these same cultures. The population of V/L/L molecules in these cultures consists almost entirely of molecules in the biosynthesis and targeting pathway. If cultures could be exposed to an infinite concentration of ~25I-VSV-GmAb, every molecule of V/L/L coming to the plasma membrane would become labeled. If lysosomal degradation could be inhibited quantitatively and instantly by leupeptin, this antibody would accumulate in lysosomes in amounts identical to the number of V/L/L molecules that had passed through the plasma membrane compartment. If this experiment were done by adding leupeptin, cycloheximide, and the ~25I-VSV-G-mAb to the culture medium simultaneously, by 2 h the V/L/L-mediated uptake of antibody would cease. If all the V/L/L passed through the plasma membrane compartment, an amount of antibody equal to the starting amount of V/L/L would have accumulated in the lysosomes. In practice, the inhibition of lysosomal degradation by leupeptin develops slowly (Fig. 4) even at high concentrations of leupeptin, and the binding of antibody to antigen proceeds with a half-time of a few minutes at practical antibody concentrations. Nevertheless, this experimental design can be employed to assess the relative amount of V/L/L passing through the cell surface en route to lysosomes at the various expression levels. The results of such experiments are tabulated in Table IV and the experimental details are described in the legend. The V/L/L-dependent uptake of ~5I-VSV-G-mAb did plateau by 100 min, as expected (data not shown), and at 2 h the cells contained an amount of ~I -VSV-G-mAb equal to the amount of V/L/L present in parallel cultures treated for 2 h with leupeptin and cycloheximide. These results were independent of the level of V/L/L expression.
Discussion
The Cytoplasmic Domain of LEPIO0 Is Necessary and SuJ~cient for Lysosomal Targeting
This study began as an exploration of the location of These results confirm and extend similar work by Williams and Fukuda (1990) that explored the targeting information in the cytoplasmic domain of hLAMP-1, which has a cytoplasmic domain identical to that of LEP100. In their work, mutations of the single Tyr in this domain to Ala, Ser, or Thr resulted in accumulation of the mutant hLAMP-1 molecules in the plasma membrane. The normal cytoplasmic domain was shown to be sufficient for lysosomal targeting of a chi- Confluent cultures of mouse cells stably transfected with DNA encoding V/L/L were induced in 10 mM butyrate containing medium for the specified times. Cell numbers were calculated from direct counts on phase micrographs of representative areas of the cultures at the time of analysis and varied between 3.2 and 3.8 • 106 per dish. Numbers of V/L/L molecules were determined as the numbers of specific ~2~I-VSV-G-mAb binding sites in saponin permeabilized cells, using t2~I-VSV-GmAb of known specific activity (see Materials and Methods). * Indicates experiment in which cell numbers in the confluent cultures were not counted but only estimated as the average of the values found in the other experiments.
Table III. Expression Levels of V/L/L in Butyrate-induced Mouse Cell Lines
meric protein that consisted of a secretory protein, human gonadotropin a-chain, linked to the transmembrane domain of VSV-G, and the cytoplasmic domain of hLAMP-1. Whether the lumenal or transmembrane domains of hLAMP-1 might also contain lysosomal targeting information was not explored.
The Lumenal Domain and Transmembrane Domain of LEPIO0 Are Neither Necessary Nor Sufficient for Lysosomal Targeting of Chimeras, and the Lumenal Domain of LEPIO0 Expressed Alone Is a Secretory Protein
Chimeras between LEP100 and VSV-G that lacked the cyto- Confluent cultures of mouse cells stably transfected with DNA encoding V/L/L were induced in 10 mM butyrate containing medium for the specified times. Numbers of V/L/L molecules per cell (colunm 2) are taken from Table III . Sets of cultures from the same batches were exposed to leupeptin (80 or 100 #g/ml) and CHX for 2 h, fix, permeabilized, and specific ~2~I-VSV-G-mAb binding sites determined. In parallel, other cultures were maintained in medium with leupeptin and CHX for 2 h at 37"C in the presence of 1 #g/ml mI-VSV-GmAb with (three or five dishes) or without (two or three dishes) a 50-fold excess unlabeled antibody. After the 2-h incubations, cultures wre washed at 4"C and radioactivity measured in a gamma counter. Number in the third colunm were calculated by multiplying the number of V/L/L molecules per cell (second column) by the ratio of specific ~251-VSV-G-mAb binding to CHX + leupeptin treated cells vs. binding to untreated cells. To obtain the numbers in the fourth column, specific uptake was calculated by subtracting uptake in the presence of 50-fold unlabeled antibody from total ~251-mAb uptake. Specific uptake was converted to molecules of antibody taken up per cell by using the known specific activity of the antibody (Materials and Methods) and the number of cells per culture dish (Table IN) .
plasmic domain of LEP100 were not targeted to lysosomes even if they contained the lumenal domain or the transmembrane domain of LEP100 or both. Since it was conceivable that a strong plasma membrane targeting signal in the cytoplasmic domains of chimeras and mutants might override a lysosomal targeting signal in the lumenal domain of LEP100, a truncated form lacking the transmembrane and cytoplasmic domains of LEP100 was expressed. It was secreted efficiently by the cells and only unprocessed precursor could be detected in cell lysates. The prevailing idea has been that lysosomal membrane proteins are sorted for targeting to the lysosomes at the trans-Golgi network (TGN) (see Green et al., 1987; Kornfeld and Mellman, 1989; Williams and Fukuda, 1990; Hunziker et al., 1991) . Soluble lysosomal proteins are sorted at this site and sent to lysosomes by a process mediated in part by M6P receptors (reviewed in Kornfeld and Mellman, 1989) . If this were the case for the lysosomal membrane proteins, any bias towards lysosomal sorting should have sent some of the truncated LEP100 to lysosomes.
The Lumenal Domain of LEPIO0 Stabilizes LEPIO0 in the Lysosome but Fails to Protect the Lumenal Domain of Nearby V/L/L Molecules
To observe the lysosomal delivery of chimeric proteins lacking the lumenal domain of LEP100 it was necessary to block lysosomal proteases with leupeptin. Even with leupeptin treatment, the VSV-G domain was clipped rapidly upon delivery of the chimeras to lysosomes. Immunofluorescence microscopy showed clearly that newly synthesized molecules are delivered to most or all of the lysosomes in the cell and therefore newly arriving molecules must exist in a surround of endogenous lysosomal membrane glycoprotein molecules. The half-life in lysosomes of chimeras containing the VSV-G domain is no more than a few minutes, whereas that of LEP100 is about two days Fambrough, 1986, 1987) .
Most or All Chimeric Molecules Directed to the Lysosome by the LEPIO0 Cytoplasmic Domain Are First Incorporated into the Plasma Membrane
The V/L/L chimera was most useful in determining the pathway taken by newly synthesized molecules to the lysosome because the VSV-G ectodomain was rapidly degraded upon delivery to lysosomes. Pulse/chase experiments (Fig. 6) showed that many of the V/L/L molecules in expressing cells had not been processed by Golgi enzymes and that Golgiprocessed molecules were degraded within minutes. Rapid loss of the population of V/L/L molecules when protein synthesis was inhibited is consistent with this interpretation of the pulse/chase experiments. Leupeptin treatment of the cells stabilized the V/L/L molecules, allowing them to accumulate in lysosomes (Figs. 2 and 4) . The movement of newly synthesized V/V/L and V/L/L through the plasma membrane was shown most graphically in the pulseexpression experiments (Fig. 7) . Although the time resolution was limited in those experiments, the detection of V/L/L molecules in the plasma membrane for up to 1 h after CHX treatment, but not after 2 h, is consistent with the kinetics of V/L/L transport through the biosynthetic pathway (includ-ing the plasma membrane) found in the pulse/chase labeling experiments. The rapid degradation of the VSV-G ectodomain in lysosomes predicts that compartments upstream from the lysosome should contain newly synthesized V/L/L molecules regardless of leupeptin treatment whereas the lysosome and compartments downstream from the lysosome should contain V/L/L molecules only following leupeptin treatment. Therefore, the relative insensitivity of the number of cell surface V/L/L molecules to leupeptin treatment is strong evidence that the plasma membrane is upstream from the lysosome (Table II) . The slightly greater number of V/L/L molecules found in the plasma membrane following 16 h of leupeptin treatment may reflect the presence of older molecules at the cell surface which, due to leupeptin treatment, have accumulated in lysosomes and have cycled out of lysosomes back to the plasma membrane, as described for LEP100 molecules in chick fibroblasts Fambrough, 1986, 1987) .
In cells expressing V/L/L, the steady-state expression of V/L/L in the plasma membrane was ".,4% of the V/L/L molecules. Since about half of the V/L/L molecules were in the high-mannose state characteristic of location in the ER (Fig.  6 A) and another fraction of V/L/L molecules must be in the Golgi apparatus, the post-Golgi compartments are expected to contain roughly 25 % of the V/L/L molecules. The 4 % of molecules in the plasma membrane are in rapid exchange with an endosomal pool of V/L/L molecules, and the size of this pool can be estimated from the curves in Fig. 8 (for discussion see Lippincott-Schwartz and Fambrough, 1987) to be about four to five times the size of the plasma membrane population, or around 20% of total V/L/L molecules. Thus the size of the combined populations of V/L/L molecules rapidly exchanging between the plasma membrane and endosomes is about the size of the entire post-Golgi population. While this study does not completely rule out the possibility that some molecules traveled more directly from the TGN to lysosomes, direct transport of a significant fraction of molecules is unlikely.
In our experiments the levels of V/L/L in the biosynthesis/ targeting pathway ranged up to "o4,500 molecules per cell (Table III) . While we do not have exact data for the quantity of the endogenous homolog of LEP100 (m-lamp-I) in these cells, this value must be similar to that reported for chick fibroblasts (Lippincott-Schwartz and Fambrough, 1986) : nearly 400,000 molecules per cell. These endogenous molecules have a metabolic half-life of about 40 h, and therefore to sustain an endogenous level of even 200,000 molecules per cell, a biosynthetic rate of about 5,000 molecules per hour would be required. Moreover, there are probably several different lysosomal membrane proteins that employ the same sorting machinery, and therefore the sorting machinery normally processes roughly 10,000 molecules/h. Thus, it seems unlikely that the exogenously expressed V/L/L disturbs the sorting/targeting behavior of the cells, even if expression levels varied considerably from cell to cell in the population. This is supported by the data in Table IV that show no effect of expression levels on V/L/L-mediated antibody uptake. The antibody uptake data do not in themselves distinguish between appearance of antigen at the plasma membrane or the flow of medium through the endocytic pathway by fluid phase uptake and then exocytosis (Besterman et al., 1981; Adams et al., 1982; Swanson et al., 1985; Swanson, 1989; Bomsel et al., 1989) with retention in the endosomes being antigen dependent. However, the experiments that directly demonstrate cycling (Fig. 8) suggest that large volume fluid flow through the endocytic pathway need not be invoked to account for antibody uptake. In either mechanism newly synthesized LEP100-type molecules must be in the plasma membrane/early endosome compartment to mediate the saturable uptake of antibody.
Recently Harter and Mellman (1992) demonstrated that high levels of over-expression of lgpl20 (a homolog of LEP100) in CHO cells resulted in higher steady state levels on the plasma membrane. Hatter and Mellman (1992) also reported immunofluorescence evidence for enhanced surface expression of another endogenous lysosomal membrane protein in the over-expressing cells and interpreted this as missorting resulting from competition with exogenously expressed lgp120 for sorting receptors in the TGN. In these experiments the expression levels were up to 15 times the endogenous; at these levels sorting might be significantly perturbed. Harter and Mellman (1992) also reported that in nontransfected pulse-labeled NRK cells 3~S-labeled lgp120 was detected at the plasma membrane (1.8 % of total) by biotinylation of cells at 0~ a level not greatly different from the 4% V/L/L found at the surface of fixed cells in our experiments. The small size of this fraction is not directly an indicator of the significance of the cell surface in the transport pathway to lysosomes. This size depends upon the balance between distribution in surface and early endosome compartments as well as the rate of exit from early endosomes in the pathway to lysosomes.
Most of the results reported here involve the behavior of V/L/L molecules. We have made the assumption that the ectodomain of VSV-G protein is behaving passively in the sorting/targeting behavior of the chimera. We cannot rule out the possibility that this domain somehow masks the targeting signal for direct delivery of LEPI00 from the TGN to lysosomes. Clearly it does not prevent efficient delivery to lysosomes via the cell surface.
The Major Pathway of Targeting LEPIO0 to the Lysosomes Includes the Plasma Membrane
Our data fit a model in which newly synthesized LEP100 is transported to the cell surface early endosome compartment, is shuttled rapidly between the plasma membrane and endosomes by endocytosis and exocytosis, and is then delivered to lysosomes. Because of this rapid shuttling, it would be very difficult to distinguish direct transport of newly synthesized LEP100 molecules from the Golgi apparatus to the plasma membrane from indirect transport via early endosomes. Our data are not consistent with the TGN being the site of sorting of LEP100-type lysosomal membrane glycoproteins for delivery to late endosomes or lysosomes.
If the plasma membrane is in the pathway for lysosomal targeting of a lysosomal membrane protein, then that protein must have a structure suitable for efficient endocytosis. A number of integral membrane proteins undergo endocytosis as a normal part of their function (Ktistakis et al., 1990) . This process generally depends upon the structure of their cytoplasmic domain, e.g., the LDL receptor (Lerman et al., 1985; Davis et al., 1987) , the EGF receptor (Prywes et al., 1986) , the polymeric IgA/IgM receptor (Mostov et  al., 1986), the transferrin receptor (Rothenberg et al., 1987) , and the Fc receptor (Miettinen et al., 1989) . At least one tyrosine occurs in the cytoplasmic domain of each of these receptors, and, where it has been examined, changing a critical tyrosine either eliminates or greatly reduces endocytosis (e.g., Davis The question of a branched pathway (as proposed by Harter and Mellman, 1992) or quantitative delivery of newly synthesized lamp-type molecules to the cell surface/early endosome cycle, as argued here, cannot easily be resolved with present technologies. Since it is virtually impossible to prove a negative, the existence of a minor direct pathway from TGN to lysosomes cannot be disproved. The apparent quantitative differences between cell types might reflect different balances of direct and indirect pathways or simply different kinetics of individual transport steps in the cell surface route to lysosomes. The biosynthetic rate of the LEP100-type lysosomal membrane proteins is very modest, for they have long lifetimes in the cells. It would not require very robust expression of sorting machinery to deliver newly synthesized molecules efficiently from the TGN to lysosomes if that were the intended biological route. There must be an important biological reason for sending LEP100 to the surface before retrieval and targeting to lysosomes. One exciting possibility is that this targeting route plays a normal role in cell-cell or cellmatrix interactions.
